about
Guidelines for the use and interpretation of assays for monitoring autophagyThe antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsChronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survivalATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.Targeting chronic myeloid leukemia stem cells.Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Autophagy in blood cancers: biological role and therapeutic implications.Role of autophagy in cancer prevention, development and therapy.Do we need more drugs for chronic myeloid leukemia?The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cellsMtss1 is a critical epigenetically regulated tumor suppressor in CML.Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.Targeting autophagy potentiates tyrosine kinaseinhibitor–induced cell death in Philadelphia chromosome–positivecells, including primary CML stem cells.Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.Hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells".Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for ThoughtGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Targeting quiescent leukemic stem cells using second generation autophagy inhibitorsAutophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemiaThe leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
P50
Q21996341-C7994BDE-62AC-4C48-BEC8-467605035B8AQ34806728-42878C34-CCCF-4364-8C1F-AB4DFF220755Q35776432-B042F3F9-05E4-4285-B6F4-2726825F614EQ37041550-24946D1E-0621-4EAF-BC0D-2C652FC40C52Q37170788-FBFAEB80-7FC2-4F86-9399-4CDCC4A47ACEQ37738541-07AC2EB6-96E4-4F4D-8632-FDBB2A58C5CBQ37892769-1FE2E15C-5812-4A88-80D3-D67250A42F4DQ37988569-9EB6E7E7-BDD2-40C3-B745-9AACB850A311Q38134372-CCB4DBA6-AB2A-4817-9252-872F9C9430B3Q38144288-A0FC5A2F-0814-4FBD-8911-FFEFDB7C4819Q38289033-0EA8EFDB-40BD-4CB6-A5B0-3396F12999EDQ39560403-B46180C4-3232-4A14-A9EC-96B5BE5A2F98Q41085680-902D674B-84D8-48FA-84A6-64D51EAAC268Q46187659-754165F0-5E10-4F0B-AAE7-47409A53E050Q46260403-92BBE306-0B60-42DE-8890-C9FBAE1AF82AQ47787188-384E9178-3B4E-4ABE-A750-6E176F7D461BQ47955211-B047F073-145D-4D82-A4A9-AE9729B37077Q50044513-94F0765D-441C-42A8-95F7-CE328F056A6CQ50195442-11976DE3-E39F-4B40-A8EC-8F8FAEC75DC2Q54570978-708711A6-77A6-4060-8CB1-1B85DA70AD55Q57491369-DEB7E9C9-122C-46E7-8C9C-A32F5294309CQ87139132-CE1CFF65-1244-4AE4-B5BE-8C2D05040725Q91304849-959D7540-477C-4FFA-A02E-8035CEE366EEQ91480444-4E2672BD-C585-4D15-8CB4-67EC9B1DB353Q92453398-25AC56BA-7646-40DC-948A-866915820AA7
P50
description
researcher ORCID ID = 0000-0003-1616-132X
@en
wetenschapper
@nl
name
G Vignir Helgason
@ast
G Vignir Helgason
@en
G Vignir Helgason
@es
G Vignir Helgason
@nl
type
label
G Vignir Helgason
@ast
G Vignir Helgason
@en
G Vignir Helgason
@es
G Vignir Helgason
@nl
prefLabel
G Vignir Helgason
@ast
G Vignir Helgason
@en
G Vignir Helgason
@es
G Vignir Helgason
@nl
P108
P106
P31
P4012
P496
0000-0003-1616-132X